SCHEMBL3182768

SCHEMBL3182768

C=CC(=O)OC(C)S(=O)(=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
TSHR P16473 2/20 0.42
HSD17B10 Q99714 1/20 0.42
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
THRB P10828 1/20 0.37
HCAR2 Q8TDS4 1/20 0.37
ATM Q13315 1/20 0.37
RAB9A P51151 3/20 0.36
ALDH1A1 P00352 3/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
NPC1 O15118 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
AKT1 P31749 1/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
CYP3A4 P08684 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5080061 0.81 ATM (0.41) LMNATSHRHSD17B10THRBATM
SCHEMBL28635736 0.81 TSHR (0.47) LMNATSHRHSD17B10CA12CA1
SCHEMBL27698103 0.80 TSHR (0.56) LMNATSHRHSD17B10CA12CA1
SCHEMBL9808496 0.80 TSHR (0.46) LMNATSHRHSD17B10CA12CA1
SCHEMBL787248 0.78 TSHR (0.44) LMNATSHRHSD17B10CA12CA1
SCHEMBL5872395 0.77 LMNA (0.45) LMNATSHRHSD17B10CA12CA1
SCHEMBL27948846 0.77 TSHR (0.47) LMNATSHRHSD17B10CA12CA1
SCHEMBL28023655 0.77 TSHR (0.50) LMNATSHRHSD17B10CA12CA1
SCHEMBL12204612 0.75 THRB (0.52) LMNATSHRHSD17B10CA12CA1
SCHEMBL27516339 0.75 RAB9A (0.37) LMNATSHRHSD17B10THRBHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662899-B2 Organic tellurium compound, process for producing the same, living radical polymerization initiator, process for producing polymer with the same, and polymer OTSUKA CHEMICAL CO., LTD. (JP) 2010-02-16 US disclosed
US-20080004366-A1 ORGANIC TELLURIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH THE SAME, AND POLYMER YAMAGO SHIGERU 2008-01-03 US disclosed
US-7276569-B2 Organic tellurium compound, process for producing the same, living radical polymerization initiator, process for producing polymer with the same, and polymer OTSUKA CHEMICAL CO., LTD. (JP) 2007-10-02 US disclosed
US-20050245714-A1 Organic tellurium compound, process for producing the same, living radical polymerization initiator, process for producing polymer with the same, and polymer OTSUKA CHEMICAL CO., LTD. (JP) 2005-11-03 US disclosed
EP-1541550-A1 ORGANIC TELLURIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH THE SAME, AND POLYMER Otsuka Chemical Co., Ltd. (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245714-A1 Organic tellurium compound, process for producing the same, living radical polymerization initiator, process for producing polymer with the same, and polymer ODC1, TERB1, TTI1 LMNA 2099/4885TSHR 1738/4885HSD17B10 801/4885
US-20080004366-A1 ORGANIC TELLURIUM COMPOUND, PROCESS FOR PRODUCING THE SAME, LIVING RADICAL POLYMERIZATION INITIATOR, PROCESS FOR PRODUCING POLYMER WITH THE SAME, AND POLYMER ODC1, TERB1, TTI1 LMNA 2099/4885TSHR 1738/4885HSD17B10 801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.